Adeno-associated virus-mediated survivin mutant Thr34Ala cooperates with oxaliplatin to inhibit tumor growth and angiogenesis in colon cancer

Oncology Reports

Volumn 25, Issue 4, 2011, Pages 1039-1046

  Xue, Zhimou ^a   Sun, Ping Hu ^b   Zhu, Li Ming ^b   Jiang, Shi Hu ^b   Qiao, Min Min ^b   Chi, Alfred L ^c   Tu, Shui Ping ^b  

^a SOOCHOW UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c CHI Scientific Inc   (United States)

Author keywords

Adeno associated virus; Angiogenesis; Apoptosis; Colon cancer; Mitotic catastrophe; Survivin mutant T34A

Indexed keywords

OXALIPLATIN; PARVOVIRUS VECTOR; SURVIVIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; COLONIC NEOPLASMS; DEPENDOVIRUS; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; INHIBITOR OF APOPTOSIS PROTEINS; MICE; MICE, INBRED BALB C; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; ORGANOPLATINUM COMPOUNDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79952222737     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1166     Document Type: Article

References (42)

1. Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J and Altieri DC: Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 152: 43-49, 1998.
2. Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917-921, 1997.
3. Deveraux QL and Reed JC: IAP family proteins - suppressors of apoptosis. Genes Dev 13: 239-252, 1999.
4. Li F, Ambrosini G, Chu EY, et al: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396: 580-584, 1998.
5. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T and Tanigawa N: Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 58: 5071-5074, 1998.
6. Sarela AI, MacAdam RC, Farmery SM, Markham AF and Guillou PJ: Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 46: 645-650, 2000.
7. Bedi A, Pasricha PJ, Akhtar AJ, et al: Inhibition of apoptosis during development of colorectal cancer. Cancer Res 55: 1811-1816, 1995.
8. Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ and Levin B: bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 55: 237-241, 1995.
9. Kawasaki H, Toyoda M, Shinohara H, et al: Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer 91: 2026-2032, 2001.
10. Chung DC: The genetic basis of colorectal cancer: insights into critical pathways of tumorigenesis. Gastroenterology 119: 854-865, 2000.
11. Zhang T, Otevrel T, Gao Z, Ehrlich SM, Fields JZ and Boman BM: Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 61: 8664-8667, 2001.
12. Hoffman WH, Biade S, Zilfou JT, Chen J and Murphy M: Transcriptional repression of the anti-apoptotic survivin gene by wild-type p53. J Biol Chem 277: 3247-3257, 2002.
13. Enger PO, Thorsen F, Lonning PE, Bjerkvig R and Hoover F: Adeno-associated viral vectors penetrate human solid tumor tissue in vivo more effectively than adenoviral vectors. Hum Gene Ther 13: 1115-1125, 2002.
14. Sarela AI, Scott N, Ramsdale J, Markham AF and Guillou PJ: Immunohistochemical detection of the anti-apoptosis protein, survivin, predicts survival after curative resection of stage II colorectal carcinomas. Ann Surg Oncol 8: 305-310, 2001.
15. Zhao J, Tenev T, Martins LM, Downward J and Lemoine NR: The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J Cell Sci 113 Pt 23: 4363-4371, 2000.
16. Yang Y, Fang S, Jensen JP, Weissman AM and Ashwell JD: Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 288: 874-877, 2000.
17. O'Connor DS, Grossman D, Plescia J, et al: Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci USA 97: 13103-13107, 2000.
18. Mesri M, Wall NR, Li J, Kim RW and Altieri DC: Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest 108: 981-990, 2001.
19. Li B, Fan J, Liu X, et al: Suppression of colorectal tumor growth by regulated survivin targeting. J Mol Med 84: 1077-1086, 2006.
20. Mah C, Byrne BJ and Flotte TR: Virus-based gene delivery systems. Clin Pharmacokinet 41: 901-911, 2002.
21. Carter PJ and Samulski RJ: Adeno-associated viral vectors as gene delivery vehicles. Int J Mol Med 6: 17-27, 2000.
22. Tu SP, Cui JT, Liston P, et al: Gene therapy for colon cancer by adeno-associated viral vector-mediated transfer of survivin Cys84Ala mutant. Gastroenterology 128: 361-375, 2005.
23. Tu SP, Jiang XH, Lin MC, et al: Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res 63: 7724-7732, 2003.
24. Goldberg R: Oxaliplatin in colorectal cancer: current studies. Oncology 14 (Suppl. 11): S42-S47, 2000.
25. O'Connor DS, Schechner JS, Adida C, et al: Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol 156: 393-398, 2000.
26. Mesri M, Morales-Ruiz M, Ackermann EJ, et al: Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Am J Pathol 158: 1757-1765, 2001.
27. Wall NR, O'Connor DS, Plescia J, Pommier Y and Altieri DC: Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res 63: 230-235, 2003.
28. Grossman D, Kim PJ, Schechner JS and Altieri DC: Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci USA 98: 635-640, 2001.
29. + T cell response specific for the tumor-shared antigen survivin in healthy donors and cancer patients. J Immunol 181: 431-439, 2008.
30. Muchmore SW, Chen J, Jakob C, et al: Crystal structure and mutagenic analysis of the inhibitor-of-apoptosis protein survivin. Mol Cell 6: 173-182, 2000.
31. Pan L, Peng XC, Leng F, et al: Therapeutic effects of survivin dominant negative mutant in a mouse model of prostate cancer. J Cancer Res Clin Oncol: Mar 9, 2010 (Epub ahead of print).
32. Yu DD, Wang CT, Shi HS, et al: Enhancement of cisplatin sensitivity in lewis lung carcinoma by liposome-mediated delivery of a survivin mutant. J Exp Clin Cancer Res 29: 46, 2010.
33. Zhen HN, Zhang X, Hu PZ, et al: Survivin expression and its relation with proliferation, apoptosis, and angiogenesis in brain gliomas. Cancer 104: 2775-2783, 2005.
34. Tran J, Rak J, Sheehan C, et al: Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun 264: 781-788, 1999.
35. Tran J, Master Z, Yu JL, Rak J, Dumont DJ and Kerbel RS: A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 99: 4349-4354, 2002.
36. Harfouche R, Hassessian HM, Guo Y, et al: Mechanisms which mediate the antiapoptotic effects of angiopoietin-1 on endothelial cells. Microvasc Res 64: 135-147, 2002.
37. Papapetropoulos A, Fulton D, Mahboubi K, et al: Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem 275: 9102-9105, 2000.
38. Zaffaroni N and Daidone MG: Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist Updat 5: 65-72, 2002.
39. Haug K, Kravik KL and De Angelis PM: Cellular response to irinotecan in colon cancer cell lines showing differential response to 5-fluorouracil. Anticancer Res 28: 583-592, 2008.
40. William-Faltaos S, Rouillard D, Lechat P and Bastian G: Cell cycle arrest by oxaliplatin on cancer cells. Fundam Clin Pharmacol 21: 165-172, 2007.
41. William-Faltaos S, Rouillard D, Lechat P and Bastian G: Cell cycle arrest and apoptosis induced by oxaliplatin (L-OHP) on four human cancer cell lines. Anticancer Res 26: 2093-2099, 2006.
42. Liu HF, Hu HC and Chao JI: Oxaliplatin down-regulates survivin by p38 MAP kinase and proteasome in human colon cancer cells. Chem Biol Interact 188: 535-545, 2010.